GlassScriptPhysician profile
Erin L Rowell
NPI 1619263696
$2,238.97
in general payments reported to CMS, 2019-2025
14 companies · $229 in 2025
The $229 reported for 2025 was more than what 85% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $156 · 2021: $324 · 2022: $296 · 2023: $582 · 2024: $531 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,341.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $385.23 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $372.60 | 2021-2024 | Xarelto |
| Inari Medical, INC. | $297.73 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Ceribell, INC. | $177.28 | 2025 | Pocket Eeg Device |
| Abbvie INC. | $177.12 | 2023-2024 | Dalvance |
| Boston Scientific Corporation | $143.62 | 2022 | |
| Chiesi USA, INC. | $138.81 | 2024-2025 | Cleviprex |
| Lilly USA, LLC | $135.75 | 2024-2025 | Zepbound, Mounjaro |
| Gilead Sciences, INC. | $124.21 | 2023 | Veklury |
| Abbott Laboratories | $103.72 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $102.48 | 2022 | |
| Novo Nordisk INC | $39.95 | 2023-2024 | Wegovy |
| Ucb, INC. | $21.01 | 2025 | Nayzilam |
| Alexion Pharmaceuticals, INC. | $19.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Rowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.